Hemab Posts $27.3M Q3 Loss, Starts Pivotal SOLARA Phase 3 in Glanzmann Thrombasthenia
COAG sits 86% above its 52-week low of $23 on elevated volume (2.3× avg).
Summary
Hemab reported a $27.3M third-quarter net loss with $430.2M in cash funding operations into 2029, and disclosed the start of its pivotal SOLARA Phase 3 trial of sutacimig in Glanzmann thrombasthenia — a single-arm design the company chose despite FDA recommending a randomized trial.
Key Events · Earnings and Guidance · COAG
-
Pivotal SOLARA Phase 3 Initiated
SOLARA enrolls approximately 75 Glanzmann thrombasthenia patients aged 12 to 70 in a 24-week standard-of-care run-in followed by 48 weeks of once-weekly subcutaneous sutacimig 0.2 mg/kg; first participants are consented and scheduled to enter the run-in during Q4 2026.
-
Single-Arm Design Over FDA Objection
Hemab is proceeding with a single-arm, intra-participant design even though the FDA recommended a randomized controlled trial, citing feasibility and patient heterogeneity — the agency could require an additional randomized study before approval.
-
Q3 Loss Widens on Clinical Spend
Net loss was $27.3M, or $0.58 per share, versus $17.1M a year earlier, as R&D rose to $24.6M from $14.6M and G&A to $5.1M from $2.5M.
-
Cash Runway Into 2029
Cash, cash equivalents and marketable securities totaled $430.2M at September 30, 2026, down from $457.5M at June 30, 2026, which the company says funds operations and capital expenditures into 2029.
Analysis · COAG · Life Sciences
For a clinical-stage biotech, the quarter itself is unremarkable: R&D spending nearly doubled to $24.6M and the net loss widened to $27.3M from $17.1M a year ago, yet $430.2M of cash still funds operations into 2029, so there is no financing overhang. The pipeline step-up is what matters. Hemab began SOLARA, the first pivotal trial of a subcutaneous prophylactic in Glanzmann thrombasthenia, enrolling roughly 75 patients with a 24-week run-in followed by 48 weeks of once-weekly sutacimig. Notably, the company chose a single-arm design even though the FDA recommended a randomized controlled trial — a real regulatory risk, since the agency could later demand an additional randomized study before approval. Against that, sutacimig's first Factor VII deficiency data (prothrombin time cut by more than half in both participants, ~5x accumulation of endogenous FVII(a)) supports the mechanism ahead of the December 14 ASH presentation.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, COAG was trading at $42.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $23.00 to $55.42. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.